Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
10
ENVB Quote, Financials, Valuation and Earnings
Last price:
$4.68
Seasonality move
:
-9.15%
Day range:
$4.62 - $4.83
52-week range:
$4.55 - $96.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
0.70x
Volume:
27.9K
Avg. volume:
1.4M
1-year change:
-91.68%
Market cap:
$2.4M
Revenue:
--
EPS (TTM):
-$81.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ENVB
Enveric Biosciences, Inc.
|
-- | -$0.55 | -- | -60% | $10.00 |
|
ABBV
AbbVie, Inc.
|
$15.6B | $1.78 | 8.54% | 103.87% | $244.68 |
|
BEAT
HeartBeam, Inc.
|
-- | -- | -- | -- | $4.63 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IBIO
iBio, Inc.
|
$25K | -$0.07 | -87.5% | -80.47% | $4.77 |
|
KTTA
Pasithea Therapeutics Corp.
|
-- | -- | -- | -92.51% | $3.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ENVB
Enveric Biosciences, Inc.
|
$4.64 | $10.00 | $2.4M | -- | $0.00 | 0% | 0.02x |
|
ABBV
AbbVie, Inc.
|
$230.01 | $244.68 | $406.5B | 173.55x | $1.64 | 2.85% | 6.83x |
|
BEAT
HeartBeam, Inc.
|
$2.58 | $4.63 | $88.9M | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$4.68 | $42.50 | $14.2M | -- | $0.00 | 0% | -- |
|
IBIO
iBio, Inc.
|
$1.87 | $4.77 | $42.1M | -- | $0.00 | 0% | 82.65x |
|
KTTA
Pasithea Therapeutics Corp.
|
$1.17 | $3.00 | $8.7M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ENVB
Enveric Biosciences, Inc.
|
-- | -0.336 | -- | 4.15x |
|
ABBV
AbbVie, Inc.
|
104% | -0.046 | 16.8% | 0.47x |
|
BEAT
HeartBeam, Inc.
|
-- | 1.449 | -- | 0.75x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IBIO
iBio, Inc.
|
5.55% | 1.666 | 19.65% | 8.21x |
|
KTTA
Pasithea Therapeutics Corp.
|
0.32% | -3.702 | 0.72% | 3.07x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ENVB
Enveric Biosciences, Inc.
|
-$40.4K | -$1.9M | -322.21% | -322.21% | -- | -$2.1M |
|
ABBV
AbbVie, Inc.
|
$10.4B | $4.6B | 3.31% | 144.3% | 29.03% | $6.6B |
|
BEAT
HeartBeam, Inc.
|
-$8K | -$5.3M | -555.14% | -555.14% | -- | -$3.2M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IBIO
iBio, Inc.
|
-$189K | -$6M | -75.48% | -88.23% | -5951% | -$5.7M |
|
KTTA
Pasithea Therapeutics Corp.
|
-$181.5K | -$3.1M | -91.9% | -92.48% | -- | -$2.9M |
Enveric Biosciences, Inc. vs. Competitors
-
Which has Higher Returns ENVB or ABBV?
AbbVie, Inc. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of 1.13%. Enveric Biosciences, Inc.'s return on equity of -322.21% beat AbbVie, Inc.'s return on equity of 144.3%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M ABBVAbbVie, Inc.66.12% $0.10 $66.1B -
What do Analysts Say About ENVB or ABBV?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 2486.21%. On the other hand AbbVie, Inc. has an analysts' consensus of $244.68 which suggests that it could grow by 6.95%. Given that Enveric Biosciences, Inc. has higher upside potential than AbbVie, Inc., analysts believe Enveric Biosciences, Inc. is more attractive than AbbVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 ABBVAbbVie, Inc.14 8 0 -
Is ENVB or ABBV More Risky?
Enveric Biosciences, Inc. has a beta of 0.223, which suggesting that the stock is 77.739% less volatile than S&P 500. In comparison AbbVie, Inc. has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.24%.
-
Which is a Better Dividend Stock ENVB or ABBV?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie, Inc. offers a yield of 2.85% to investors and pays a quarterly dividend of $1.64 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. AbbVie, Inc. pays out 263.15% of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or ABBV?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than AbbVie, Inc. quarterly revenues of $15.8B. Enveric Biosciences, Inc.'s net income of -$1.9M is lower than AbbVie, Inc.'s net income of $178M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while AbbVie, Inc.'s PE ratio is 173.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus 6.83x for AbbVie, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M ABBVAbbVie, Inc.6.83x 173.55x $15.8B $178M
-
Which has Higher Returns ENVB or BEAT?
HeartBeam, Inc. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of --. Enveric Biosciences, Inc.'s return on equity of -322.21% beat HeartBeam, Inc.'s return on equity of -555.14%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M BEATHeartBeam, Inc.-- -$0.15 $406K -
What do Analysts Say About ENVB or BEAT?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 2486.21%. On the other hand HeartBeam, Inc. has an analysts' consensus of $4.63 which suggests that it could grow by 68.8%. Given that Enveric Biosciences, Inc. has higher upside potential than HeartBeam, Inc., analysts believe Enveric Biosciences, Inc. is more attractive than HeartBeam, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 BEATHeartBeam, Inc.2 1 0 -
Is ENVB or BEAT More Risky?
Enveric Biosciences, Inc. has a beta of 0.223, which suggesting that the stock is 77.739% less volatile than S&P 500. In comparison HeartBeam, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ENVB or BEAT?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HeartBeam, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. HeartBeam, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or BEAT?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than HeartBeam, Inc. quarterly revenues of --. Enveric Biosciences, Inc.'s net income of -$1.9M is higher than HeartBeam, Inc.'s net income of -$5.3M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while HeartBeam, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus -- for HeartBeam, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M BEATHeartBeam, Inc.-- -- -- -$5.3M
-
Which has Higher Returns ENVB or CVM?
CEL-SCI Corp. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of --. Enveric Biosciences, Inc.'s return on equity of -322.21% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About ENVB or CVM?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 2486.21%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 808.12%. Given that Enveric Biosciences, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Enveric Biosciences, Inc. is more attractive than CEL-SCI Corp..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is ENVB or CVM More Risky?
Enveric Biosciences, Inc. has a beta of 0.223, which suggesting that the stock is 77.739% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock ENVB or CVM?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or CVM?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Enveric Biosciences, Inc.'s net income of -$1.9M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns ENVB or IBIO?
iBio, Inc. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of -5720%. Enveric Biosciences, Inc.'s return on equity of -322.21% beat iBio, Inc.'s return on equity of -88.23%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M IBIOiBio, Inc.-189% -$0.11 $59.3M -
What do Analysts Say About ENVB or IBIO?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 2486.21%. On the other hand iBio, Inc. has an analysts' consensus of $4.77 which suggests that it could grow by 154.9%. Given that Enveric Biosciences, Inc. has higher upside potential than iBio, Inc., analysts believe Enveric Biosciences, Inc. is more attractive than iBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 IBIOiBio, Inc.6 0 0 -
Is ENVB or IBIO More Risky?
Enveric Biosciences, Inc. has a beta of 0.223, which suggesting that the stock is 77.739% less volatile than S&P 500. In comparison iBio, Inc. has a beta of 1.135, suggesting its more volatile than the S&P 500 by 13.459%.
-
Which is a Better Dividend Stock ENVB or IBIO?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. iBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or IBIO?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than iBio, Inc. quarterly revenues of $100K. Enveric Biosciences, Inc.'s net income of -$1.9M is higher than iBio, Inc.'s net income of -$5.7M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while iBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus 82.65x for iBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M IBIOiBio, Inc.82.65x -- $100K -$5.7M
-
Which has Higher Returns ENVB or KTTA?
Pasithea Therapeutics Corp. has a net margin of -- compared to Enveric Biosciences, Inc.'s net margin of --. Enveric Biosciences, Inc.'s return on equity of -322.21% beat Pasithea Therapeutics Corp.'s return on equity of -92.48%.
Company Gross Margin Earnings Per Share Invested Capital ENVBEnveric Biosciences, Inc.-- -$10.81 $3.5M KTTAPasithea Therapeutics Corp.-- -$0.41 $12.2M -
What do Analysts Say About ENVB or KTTA?
Enveric Biosciences, Inc. has a consensus price target of $10.00, signalling upside risk potential of 2486.21%. On the other hand Pasithea Therapeutics Corp. has an analysts' consensus of $3.00 which suggests that it could grow by 156.41%. Given that Enveric Biosciences, Inc. has higher upside potential than Pasithea Therapeutics Corp., analysts believe Enveric Biosciences, Inc. is more attractive than Pasithea Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings ENVBEnveric Biosciences, Inc.0 0 0 KTTAPasithea Therapeutics Corp.1 0 0 -
Is ENVB or KTTA More Risky?
Enveric Biosciences, Inc. has a beta of 0.223, which suggesting that the stock is 77.739% less volatile than S&P 500. In comparison Pasithea Therapeutics Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ENVB or KTTA?
Enveric Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pasithea Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enveric Biosciences, Inc. pays -- of its earnings as a dividend. Pasithea Therapeutics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENVB or KTTA?
Enveric Biosciences, Inc. quarterly revenues are --, which are smaller than Pasithea Therapeutics Corp. quarterly revenues of --. Enveric Biosciences, Inc.'s net income of -$1.9M is higher than Pasithea Therapeutics Corp.'s net income of -$3M. Notably, Enveric Biosciences, Inc.'s price-to-earnings ratio is -- while Pasithea Therapeutics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enveric Biosciences, Inc. is 0.02x versus -- for Pasithea Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENVBEnveric Biosciences, Inc.0.02x -- -- -$1.9M KTTAPasithea Therapeutics Corp.-- -- -- -$3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
